ABBEY BAUMAN: Open Payments
NPI 1467072066 · SIOUX FALLS, SD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$730 in 45 payments from 8 companies in 2025. Trend: 2023 $96 · 2024 $138 · 2025 $730
Food & beverage: $730
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 24 | $338 |
| Corium, LLC | 6 | $101 |
| Teva Pharmaceuticals USA, Inc. | 4 | $78 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $66 |
| Neurocrine BioSciences, Inc. | 3 | $54 |
| Vanda Pharmaceuticals Inc. | 1 | $40 |
| Alkermes, Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
Products named: REXULTI, Azstarys, UZEDY, CAPLYTA, INGREZZA, ABILIFY MAINTENA, FANAPT, ARISTADA.
Industry payments across SD — which companies pay providers there.
